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can promote sufficient virilization. When spermatogenesis is 
required, pulsatile GnRH infusion or gonadotropin therapy 
can be conducted. For most patients, hormonal replacement 
therapy is considered to be a life-long therapy. However, few 
patients may gradually recover from hypogonadism during 
treatment.6,7 Mutations in GnRHR  (138850),6,8,9 CHD7  (608892),8 
FGF8  (600483), FGFR1  (136350),6,8,10 PROK2/PROKR2 (607002, 
607123),11 KISS1/KISSR (603286, 604161), TAC3/TACR3  (162330, 
162332)12 and KAL1 (300836)11 have been found in some reversal 
patients. It is speculated that the effects of testosterone on GnRH 
neuron plasticity may be an underlying mechanism. Our knowledge 
on reversal and its predictive factors is still scarce due to limited cases.
We retrospectively investigated the clinical features of 18 IHH 
patients who had recovered from impaired HPGA function after 
hormonal therapies and follow-up for 4–15 years. Furthermore, several 
favorable predictive factors for reversal were identified.
MATERIALS AND METHODS
Study deﬁnition
A diagnosis of IHH includes the following three criteria:  (1) no 
secondary sexual characteristic development at 18  years of age; 
(2) serum total testosterone levels below 100 ng dl−1 (3.47 nmol l−1) 
INTRODUCTION
Hypothalamic-pituitary-gonadal axis (HPGA) plays a major role in the 
regulation of the male reproductive endocrine system. During late fetal 
and early neonatal periods, gonadotropin secretion, which is stimulated 
by pulsatile hypothalamic gonadotropin-releasing hormone (GnRH), 
is necessary for Leydig and Sertoli cell proliferation as well as future 
spermatogenesis.1 Before puberty, HPGA is in a relatively inactive 
state. During puberty, HPGA reactivation triggers the development 
of secondary sexual characteristics and maintains sexual maturation.
Idiopathic hypogonadotropic hypogonadism (IHH) is traditionally 
considered to be a life-long disease due to an isolated deficiency 
or dysfunction of GnRH neurons. Mutations in genes such as 
KAL1 (300836), FGF8 (600483), FGFR1 (136350), PROK2/PROKR2 
(607002, 607123), KISS1/KISSR  (603286,604161), or TAC3/TACR3 
(162330, 162332)2,3 can cause IHH. Patients with hyposmia or anosmia 
are defined as having Kallmann syndrome (KS), and those with normal 
olfactory status are defined as nIHH. IHH patients may share multiple 
of the above-mentioned gene mutations4 and may present with a wide 
spectrum of puberty development.5
No puberty development or virilization, delayed epiphysis 
closure, small testes and penis, and azoospermia are main clinical 
features of male IHH patients. Testosterone replacement therapy 
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with isolated gonadotropin deficiency;  (3) normal sellar magnetic 
resonance image (MRI).6
Complaints of anosmia in addition to olfactory bulb and tract 
dysplasia images in an MRI will lead to a KS diagnosis. Otherwise, the 
patient is diagnosed as nIHH. Additional subjective olfactory function 
tests were conducted by the by University of Pennsylvania Smell 
Identification Test,13 and objective tests (olfactory evoking electronic 
potential test14) were conducted in a small proportion of KS patients.
Considering that testosterone production and spermatogenesis are 
two main indications of testicle function, our criteria for IHH reversal 
were: after discontinuation of any hormonal therapy for 6 months, either 
endogenous testosterone rises above 270 ng dl−1 (9.4 nmol l−1)6 or serum 
testosterone levels gradually increased above 150 ng dl−1 (5.2 nmol l−1) 
accompanied with increased testicle size, normal spontaneous sperm 
production, and normal erectile function and ejaculation.
Study population and data collection
A total of 354 IHH patients were included. Follow-up was conducted for 
these patients for more than 4 years at Peking Union Medical College 
Hospital between January 2005 and December 2011. Among them, 
18 patients were classified into the reversal group and the remaining 
336 patients were classified into the nonreversal group. For each patient, 
clinical presentation, past medical history (including cryptorchidism, 
micropenis and previous treatment) and family history were recorded 
during his first visit to our clinic. Follow-up information including 
virilization after testosterone therapy, gonadotropin-induced 
spermatogenesis, endogenous gonadotropins and testosterone, and 
testicle size (by Prader orchidometer methodology) were recorded in 
the medical profiles. The study was approved by the ethics committee of 
the Peking Union Medical College Hospital. Written informed consent 
was obtained from all of the participants.
Treatment and follow‑up
Testosterone replacement therapy included 40–80 mg oral testosterone 
undecanoate three times per day or intramuscular 250 mg testosterone 
undecanoate injection per month. If spermatogenesis was required, 
intramuscular human chorionic gonadotropin (HCG) (2000 U) and 
human menopausal gonadotropin (HMG) (150 U) were administered 
twice weekly.
Regular follow-up was conducted at a 6–12  month interval. 
Secondary sexual characteristics, testicle size, gonadotropins and 
testosterone levels were measured on each visit. If a patient exhibited 
testicle growth and rising endogenous gonadotropins, semen 
analysis was conducted, and the hormonal therapy was suspended 
for 6 months. If the patient did not meet the definition of reversal 
on the next follow-up, testosterone or gonadotropins were resumed 
for 6–12  months. Then, the patient was reevaluated. For a patient 
with testicle size over 6 ml, his hormonal therapy was intermittently 
suspended to evaluate the capacity of endogenous testosterone 
production and spermatogenesis.
Hormone assay and triptorelin stimulating test
At baseline, a GnRH analog (triptorelin) stimulating test was conducted 
to evaluate the potential reservoir of HPGA function. After 100 μg 
triptorelin was intramuscularly injected, luteinizing hormone  (LH) 
and follicular stimulating hormone (FSH) were measured basally and 
after 60  min. Our pervious data demonstrated that 92.3% of male 
IHH patients had LH60 min lower than 4  IU l−1, whereas this level is 
usually higher than 12 IU l−1 in normal male adults.15 FSH and LH 
levels were measured using commercial kits by chemiluminescence 
(ACS: 180 Automatic Chemiluminescence Systems, Bayer, Germany). 
The intra- and inter-assay coefficients of LH variation were 5.6% and 
6.6%, respectively. The lowest measurable limit of LH was 0.02 IU l−1.
Statistical analysis
SPSS version 11.0 for Windows (SPSS, Chicago, IL, USA) was used 
for data analysis. Normal distributive data were expressed as the 
mean  ±  s.d., and nonnormal distribution data were expressed as 
medians. The paired-sample t-test was used to compare the differences 
before and after the reversal. Basal LH levels and basal testicle size 
between reversal and non-reversal groups were compared using an 
independent t-test. Comparison of the cryptorchidism rate between 
the two groups was performed by Chi-square test. Stimulated LH 
levels between the two groups were compared by univariate analysis 
of variance to control the influence of testicular size on the results. 
Statistical significance was set at P < 0.05.
RESULTS
Clinical features of idiopathic hypogonadotropic hypogonadism 
patients
At the initial visit to our clinic, the patients (n = 354) were generally in 
good conditions with normal routine blood and urine test results and 
normal liver and renal function. Systemic diseases such as malnutrition, 
depression, nephrotic syndrome and chronic diarrhea were excluded. 
In all IHH patients, 203 were KS and 151 were nIHH. Tests including 
a subjective olfactory function test and an olfactory evoking electronic 
potential test were performed in 112 and 48 KS patients, respectively. 
All of the patients who underwent the subjective olfactory function 
test had poor scores. For 48 KS patients who received the olfactory 
evoking electronic potential test, no electronic potential responses 
were observed.
In total, 18  patients were identified as reversal  (Figure  1). Of 
these, five were KS. The clinical characteristics including age of 
diagnosis, complicating diseases, testicle sizes and treatments were 
listed in Table 1. They were followed-up for a median of 5.6 years 
(range from 4 to 15 years). The median age at diagnosis and reversal 
was 20 years (range 17–31 years) and 24 years (range 21–34 years), 
respectively. In the reversal group, 44.4% of patients  (8/18) had a 
history of HCG treatment, which may have increased testicular 
volumes at the initial visit to our hospital and promoted bone 
maturation (Table 1).
Figure 1: Diagnosis, reversal time and hormonal therapies for the reversed 
idiopathic hypogonadotropic hypogonadism patients (n = 18).
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In the non-reversal group (n = 336), 59.0% of patients were KS. 
Of these, 26% had a history of HCG treatment. The median follow-up 
time was 5.2 years (range from 4 to 32 years). In the non-reversal group, 
212 patients (63.1%) received gonadotropin (HCG + HMG) therapy 
for spermatogenesis during the follow-up.
Testicle sizes
In the reversible group, two patients  (11.1%) had histories of 
cryptorchidism, and orchidopexy surgeries were performed at 3–5 years 
of age. At the initial visit, the reversible patients had larger testicle sizes 
than the nonreversible patients; 5.1 ± 2.6 ml versus 1.5 ± 0.3 ml (P < 0.05). 
During the follow-up, the testicle size in the reversible group increased 
from 5.1 ± 2.6 ml to 15.1 ± 3.8 ml; P < 0.01 (Figure 2).
In the non-reversal group, 76 patients (22.6%) had cryptorchidism, 
which was significantly higher than the reversal group (11.1%; P < 0.01). 
In this group, testicle sizes increased only in patients receiving 
gonadotropin therapy. Once they stopped gonadotropin therapy, testicle 
sizes stopped increasing, and testosterone levels dropped to near zero.
Baseline luteinizing hormone, testosterone and gonadotropin‑releasing 
hormone analog stimulating test
At the initial visit, basal LH levels in the reversal group were 
significantly higher than the nonreversal group; 1.0 ± 0.7 IU l−1 versus 
0.4 ± 0.4 IU l−1 (P < 0.05). At the initial visit, serum testosterone levels 
between the two groups were similar. After follow-up for 4–15 years, the 
testosterone concentration in the reversible group gradually increased 
from 41 ± 23 ng dl−1 to 353 ± 171 ng dl−1.
At the time of the initial visit, LH levels in the reversal group after 
GnRHa (triptorelin) stimulation were 28.3 ± 22.6 IU l−1 (n = 14), which 
was significantly higher than the nonreversal group 1.9 ± 1.1 IU l−1 
(n = 163) (P < 0.01, Figure 3). Of the reversible patients, 86% (11/14) 
had LH60 min above 12 IU l−1, while in the nonreversal group, 4% of them 
achieved such a high level.
Spermatogenesis in the reversal group
Semen was successfully collected from twelve patients  (12/18), 
and the median sperm count was 25 million ml−1  (range from 
5.1 to 126 million ml−1, Table 2). Other patients were not able to provide 
semen samples. In the reversible group, three patients impregnated 
their wives spontaneously.
Follow‑up after hypothalamic‑pituitary‑gonadal axis reversal
In general, testosterone concentrations in the reversible group were 
353  ±  171  ng dl−1 after they discontinued any hormonal therapies 
for 6  months, which was significantly lower than the healthy 
group 415.4 ± 112.4 ng dl−1 (P < 0.05).
Patient 3 had a reversal at 26  years of age. His testosterone 
was 218  ng dl−1, and his sperm count was 86 million ml−1. During 
the next 2  years of follow-up, his testosterone level gradually 
decreased to 49 ng dl−1. At 28 years of age, he restarted gonadotropin 
Table 1: The clinical features of IHH patients who had reversed reproductive axis function (n=18)
Patient 
number
Diagnosis BMI (kg m−2) History of HCG treatment Cryptorchidism, micropenis and other clinical features Hormonal 
treatment
1 nIHH 19.2 ‑ ‑ T
2 KS 22.3 HCG for 2 months at the age of 18 years Micropenis; mixed deafness in the left ear; conductive 
deafness in the right ear
T
3 KS 20.1 HCG for 3 months at the age of 21 years Testosterone decreased at the age of 28 years. He 
restarted HCG treatment for 1‑year and then stopped. 
After that, his testosterone maintained in normal range
T
4 KS 25.9 ‑ Micropenis; overweight T‑HCG/HMG‑T
5 nIHH 25.6 ‑ Overweight T
6 nIHH 23.4 ‑ His testosterone decreased at the age of 24 years and he 
continued HCG/HMG therapy for 2 years and still on
T‑HCG/HMG‑T
7 nIHH 20.4 ‑ ‑ T
8 nIHH 20.1 ‑ ‑ T
9 nIHH 27.2 HCG for 12 months at age of 16 years Overweight T
10 KS 22.6 HCG for 18 months at the age of 14 years ‑ T
11 nIHH 23.6 ‑ ‑ T
12 nIHH 22.6 ‑ Micropenis T
13 nIHH 21.2 HCG for 2 months at the age of 15 years Cryptorchidism; orchidopexy surgery at 3 years of age; 
micropenis; mental retardation
T
14 nIHH 29.7 HCG for 8 months at age of 21 years Obesity T
15 nIHH 18.7 ‑ ‑ T
16 KS 26.6 HCG for 2 months at age of 21 years Micropenis; overweight; weight loss from 95 kg to 77 kg 
for 2 years; Relapsed to IHH 5 years later
T‑HCG/HMG
17 nIHH 30.6 ‑ Bilateral cryptorchidism and two operations were 
conducted at 3 and 5 years of age. Obesity
T‑HCG/HMG
18 nIHH 19.6 HCG for 6 months at age of 17 years ‑ HCG/HMG
BMI: body mass index; Overweight: BMI ≥24.0–27.9 kg m−2; Obesity: BMI ≥28 kg m−2; KS: kallmann syndrome; T: testosterone replacement therapy; HCG: human chorionic 
gonadotropin; HMG: human menopausal gonadotropin; IHH: idiopathic hypogonadotropic hypogonadism
Figure 2: Changes in testosterone and testicular volume before and after 
reversal (n = 18). All of the reversal patients exhibited increased testosterone 
levels and testicle volumes.
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therapy  (HCG  +  HMG), and his testosterone level increased to 
285  ng dl−1. After 1  year, he stopped therapy again; since then, his 
testosterone and spermatogenesis maintained at normal levels.
Serum testosterone levels also decreased in patient 6. He had a 
reversal at 23 years of age with testosterone level of 812 ng dl−1 and 
sperm count of 5.1 million ml−1. He resumed testosterone replacement 
therapy 1 year later. The testosterone levels and sperm counts in patients 
4 and 9, although relatively low, were sustained during the follow-up.
Patient 16 was admitted to our hospital when he was 29 years old. 
He was 189  cm tall and weighed 95  kg. He received testosterone 
replacement therapy for 2 years. During this period, he lost weight 
to 77 kg by exercise and diet control. He was diagnosed as a reversal 
at 31 years old when his testosterone increased to 435 ng dl−1 without 
sperm count measurement (“ND” in Table 2). After 5 years, he came 
to our hospital due to erectile dysfunction. His weight was maintained 
at 80 kg. His testosterone level was 26 ng dl−1, and his sperm count was 
2.3 million ml−1. Gonadotropin therapy commenced, and normal sexual 
function and sperm counts were acquired.
For the other patients, gonadotropin and testosterone levels were 
in the normal range, and no erectile dysfunction was reported.
To identify any predictive factors for relapse to hypogonadism, the 
reversible patients were further divided into two subgroups. Patients 
3, 4, 6, 9, 16 were included in group one due to their low testosterone 
levels or hypogonadism relapse. The other patients were included in 
group  2. No significant differences were observed in the basal and 
stimulated gonadotropins or in testicle size between the two subgroups.
DISCUSSION
This retrospective study identified that 5.1% (18/354) of IHH patients 
restored their gonadal function after discontinuation of hormonal 
therapy. Of the patients, fifteen out of 18 restored their HPGA 
function before 30 years old. Compared with nonreversal patients, 
they had higher basal and stimulated LH levels and larger baseline 
testicle size.
Figure 3: Serum luteinizing hormone (LH) levels after triptorelin stimulation 
were remarkably higher in the reversal group than in the nonreversal group 
(P < 0.01). At the time of diagnosis, 78.6% of the reversible patients (11/14) 
had LH60 min levels above 12 IU l
−1 after triptorelin stimulation, while in the 
nonreversal group, only 4% of them achieved such a high level. These results 
indicate that reversible patients may retain partial reproductive axis function 
at initial diagnosis.
Table 2: Hormone levels and testicular volumes in the reversal IHH patients (n=18)

























1 22 2.1 0.8 46 5 ND 26 1.9 2.8 378 20 ND
2 21 1.5 0.9 3 2 28.3 24 2.8 3.6 215 15 63*
3 24 1.4 0.7 58 5 33.8 26 3.5 2.5 218 10 86
4 23 1.2 0.5 38 2 12.6 28 3.8 3.5 155 10 20
5 31 2.6 0.9 52 10 ND 34 4.5 2.8 300 20 5.6
6 19 1.1 0.7 0 3 31.8 23 1.2 1.5 812 15 5.1
7 20 1.9 1.7 92 5 15.6 22 2.2 2.8 249 20 25
8 18 0.8 0.2 49 2 39.3 23 1.9 2.3 597 12 ND
9 21 1.5 0.84 44 6 6.7 23 3.7 2.9 155 16 46
10 18 0.7 1 53 12 19.3 21 0.7 1.7 245 16 49
11 19 1.6 0.1 64 5 ND 32 2.2 1.4 464 8 14
12 17 3.5 0.6 5 5 ND 27 6.9 4.2 348 20 72
13 17 6.6 3.2 45 4 97.4 23 13.9 8.4 522 12 ND
14 25 2.3 1.5 48 5 15.3 30 2.7 3 365 14 ND#
15 18 2.3 1.2 35 4 18.6 22 4.5 3.6 510 18 126
16 29 2.2 1.6 18 6 24.6 31 2.5 3.8 435 16 ND
17 20 2.5 2.6 56 4 27 24 3.2 4.3 248 10 ND
18 18 1.0 0.4 38 10 7.8 23 1.5 1.4 305 18 25&
Reversal 
patients (n=18)




21.6±3.3 2.1±0.7 0.4±0.4 48±29 1.5±0.3 1.9±1.1 (n=163) 26.6±3.8 1.9±0.7 0.7±0.4 ‑ 1.4±0.2 ND
Healthy men (n=50) ‑ ‑ ‑ ‑ ‑ 23.7±7.8 ‑ 4.0±2.2 3.3±1.2 415±112 22.2±3.4 ND
*Impregnate his wife at the age of 26 years; #Impregnate his wife at the age of 30 years; &His wife got pregnant for two times. ND: not done; LH: luteinizing hormone; FSH: follicular 
stimulating hormone; T: testosterone; GnRHa: gonadotropin releasing hormone agonist (triptorelin); IHH: idiopathic hypogonadotropic hypogonadism
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The definition of reversal from IHH has not been clearly determined. 
One study defined it as endogenous total testosterone levels above 
270 ng dl−1 after discontinuation of all hormonal therapy for 6 months.6 
Another study defined the reversal based on spontaneous testicular 
growth and normal reproductive hormone levels without any symptoms 
of hypogonadism.8 Our definition was made considering the following: 
first, testosterone levels in healthy male adults vary greatly from 260 
to 1180 ng dl−1 and are influenced by many factors such as obesity16 
and SHBG levels.17 There is trend of overweight and obesity in IHH 
patients, who have a PROK2/PROK2R mutation.18 Thus, the reversed 
obese patients may have relatively lower total testosterone levels. 
Second, spermatogenesis, which does not always parallel endogenous 
testosterone, is an important indicator of normal HPGA function and 
should be included in the definition. Finally, it is noted that in reversal 
group, restoration of HPGA function may take several years.6 Therefore, 
the trend of increasing endogenous gonadotropins, testosterone and 
testicle size is more reliable than transient testosterone measurement. 
Considering these facts, we designed new criteria for reversal in this 
study: endogenous testosterone increases above 270 ng dl−1 (9.4 nmol l−1) 
after discontinuation of any hormonal therapy for 6 months or gradually 
increasing serum testosterone levels above 150 ng dl−1 (5.2 nmol l−1) 
accompanied by increased testicle size, normal spontaneous sperm 
count and absence of symptoms of hypogonadism. By this definition, 
18 patients were recruited.
In the reversal group, 11 of 18 were included due to testosterone 
levels above 270 ng dl−1. Another 7 of 18 are included with testosterone 
levels above 150  ng dl−1 along with normal sperm production and 
increased testicular volume. Reversal incidence was 5.1% in our study, 
which is lower than 10%6 and 8%8 reported by the other two studies. 
If the testosterone level above 270 ng dl−1 were the only diagnostic set 
point, reversal incidence would be 3.1%, which is much lower than 
the previously reported data. A  reasonable explanation for the low 
incidence of reversal is that the participants in our study generally 
had smaller testicle volumes, indicating more severe defects in HPGA 
reservation. In Raivio et  al.’s study,6 the average testicle size in the 
nonreversal IHH patients was 4 ± 3ml, while it was 1.5 ± 0.3 ml in 
our study. The reversal incidence in our study was statistically more 
powerful due to the larger sample size.
Baseline testicle size in the reversal group was 5 ± 3 ml, which 
was significantly larger than the nonreversal group. This phenomenon 
was also documented by other studies.6,8 In their studies, baseline 
testicle volume in the reversal group was 8 ± 5 ml  (n  =  15)6 and 
5  ±  2  ml  (n  =  6),8 respectively. In IHH patients, cryptorchidism is 
a sign of severe impairment of HPGA function, while larger testes 
indicate a better potential of HPGA function.5 Larger testicular volume 
is also a consistent favorable predictor for gonadotropin-induced 
spermatogenesis.19–22 Therefore, testicle size reflects the degree of 
exposure to endogenous gonadotropins and provides a reliable and 
simple predictor for possible reversal. Conversely, as observed in our 
study, previous HCG treatment may also contribute to a larger testicle 
size. Therefore, the compound influence of endogenous and exogenous 
gonadotropins on testicle size should be carefully weighed.
Another interesting finding was that the reversal group initially had 
a higher basal LH level than the nonreversal group. This difference was 
further magnified using a GnRHa (triptorelin) stimulating test in which 
stimulated LH levels substantially increased in the reversible patients. 
Of these patients, 78.6% had stimulated LH levels above 12  IU l−1, 
while in the nonreversal group, stimulated LH levels were usually less 
than 4 IU l−1 (1.9 ± 1.1 IU l−1). Our previous data have demonstrated 
that 92% of IHH patients (n = 57) and 81% of pan-hypopituitarism 
patients  (n  =  31) had a stimulated LH level below 4  IU l−1, while 
48% of boys with constitutional delayed puberty (n = 29) and 96% 
of postpuberty adolescence (n = 28) had stimulated LH levels above 
12 IU l−1.15 Therefore, stimulated LH levels above 12 IU l−1 indicate 
a good gonadotropin reserve and partially activated HPGA 
(more information is available in the supplement).
The above clinical features indicate that for most reversal patients, 
HPGA function is partially or subnormally activated when the IHH 
diagnosis was initially made. Although it is difficult to qualitatively 
evaluate HPGA function, testicular volume, penis size, basal and 
stimulated levels of LH, inhibin B and Mullerian inhibitory substance 
may reflect the degree of HPGA dysfunction severity.5 Among these 
factors, testicular volume and stimulated LH measurement is mostly 
available. Pulsatile LH monitoring is a good parameter for evaluating 
HPGA function, and pulsatile LH restoration was demonstrated in 
reversal IHH patients.6 However, it is seldom used in clinical practice 
due to its inconvenience.
The reversal mechanisms are still undetermined. First, the reversal 
is an extreme model of delayed puberty and is on the end of the wide 
spectrum of clinical manifestations of IHH. In a family with the same 
FGFR1 mutation,10 brothers reportedly presented with normal, delayed 
or absent puberty, indicating that delayed puberty is a variant clinical 
manifestation of IHH. However, a recent study did not find any coding 
mutations in the FGFR1, GNRHR, TAC3 and TACR3 genes in 64 boys 
with delayed puberty, indicating that other factors may be involved 
in puberty timing.23 Elks and her colleagues identified 32 new loci 
associated with time of menarche by a meta-analysis of 32 genome-wide 
association studies. Among these loci, four were associated with body 
mass index (BMI) (FTO, SEC16B, TRA2B and TMEM18), three were 
involved in energy homeostasis (BSX, CRTC1 and MCHR2) and three 
were involved in hormonal regulation (INHBA, PCSK2 and RXRG).24 
Therefore, pubertal development is elaborately regulated by multiple 
genetic factors as well as ethnic and social economic status. Second, 
exposure to high testosterone concentrations may promote GnRH 
neuron maturation and activate HPGA function as posited by Raivio 
et al.6 This theory is also supported by the facts that central precocious 
puberty may be induced in patients with 21-hydoxlase deficiency after 
the adrenal-derived androgen was suppressed by glucocorticoids.17,25
It is important to note that reversal patients had a greater risk of 
hypogonadism relapse or were sustained at low testosterone levels 
for a long period such as patients 3, 4, 6, 9 and 16. This phenomenon 
was also observed and investigated by several other studies.6,8,26 A 
recent study conducted by Sidhoum et al.26 demonstrated that 5 of 
44 male patients could not sustain their reversal and again developed 
hypogonadotropism. Therefore, it is reasonable to assume that for 
some reversible patients, GnRH neurons may need more time to 
synchronize for gonadotropin secretion, or HPGA function is only 
partially activated due to the limited number of GnRH neurons.
In the reversal group, 6 of 18 patients (33.3%) were overweight 
or obese  (BMI 25.6–30.6  kg m−2). Of six patients who relapsed 
into hypogonadism or sustained low total testosterone levels, three 
were overweight or obese  (patient 4, 9 and 16). Lower levels of 
total testosterone are associated with obesity in men, especially for 
severe obesity,27 due to lower SHBG, excessive aromatase activity28 
and reduced LH secretion.17,25 In our study, the patients were of 
mild adiposity, and therefore their body weights did not remarkably 
influence total testosterone levels.
Our study had some limitations. First, although the follow-up in 
this study was above 4 years, it is possible that with a longer tracking 
time, more reversal cases may occur. Second, the frequency and 
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amplitude of pulsatile LH secretion was not measured. Intermittent 
LH peaks at night is the first sign of puberty initiation and may 
provide more information about HPGA function. We believed that the 
triptorelin stimulation test may be able to substitute for pulsatile LH 
measurement and may accurately reflect HPGA function.
CONCLUSION
Our study demonstrated that reversal incidence in IHH patients was 
approximately 5%, and most reversal occurred in patients with partially 
activated HPGA function. Testicle size and GnRHa (triptorelin)-stimulated 
LH levels, which reflect HPGA defect severity, are two reliable predictive 
factors for reversal. Because overtreatment should be avoided for patients 
with potential for reversal, the two predictors may guide us identify these 
patients and plan their therapeutic regimens accordingly.
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